Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Viking Therapeutics stock

VKTX
US92686J1060
A12GD6

Price

0
Today +/-
-0
Today %
-0 %

Viking Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Viking Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Viking Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Viking Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Viking Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Viking Therapeutics Stock Price History

DateViking Therapeutics Price
2/14/20250 undefined
2/13/202530.48 undefined
2/12/202529.50 undefined
2/11/202529.32 undefined
2/10/202529.96 undefined
2/9/202530.17 undefined
2/6/202532.56 undefined
2/5/202531.46 undefined
2/4/202533.50 undefined
2/3/202532.37 undefined
2/2/202531.52 undefined
1/30/202532.75 undefined
1/29/202533.69 undefined
1/28/202533.43 undefined
1/27/202534.32 undefined
1/26/202533.46 undefined
1/23/202534.50 undefined
1/22/202534.94 undefined
1/21/202534.05 undefined
1/20/202532.87 undefined
1/16/202532.65 undefined

Viking Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Viking Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Viking Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Viking Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Viking Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Viking Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Viking Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Viking Therapeutics’s growth potential.

Viking Therapeutics Revenue, EBIT and net profit per share

DateViking Therapeutics RevenueViking Therapeutics EBITViking Therapeutics Net Income
2030e2.09 B undefined0 undefined1.2 B undefined
2029e1.08 B undefined292.27 M undefined461.75 M undefined
2028e384.61 M undefined-104.58 M undefined-11.19 M undefined
2027e95.59 M undefined-337.09 M undefined-273.46 M undefined
2026e23.1 M undefined-275.76 M undefined-240.06 M undefined
2025e2.13 M undefined-213.04 M undefined-177.56 M undefined
20240 undefined-150.92 M undefined-109.96 M undefined
20230 undefined-100.83 M undefined-85.9 M undefined
20220 undefined-70.36 M undefined-68.87 M undefined
20210 undefined-55.68 M undefined-54.99 M undefined
20200 undefined-42.66 M undefined-39.5 M undefined
20190 undefined-32.69 M undefined-25.78 M undefined
20180 undefined-26.16 M undefined-22.06 M undefined
20170 undefined-19.07 M undefined-20.58 M undefined
20160 undefined-13.85 M undefined-14.73 M undefined
20150 undefined-12 M undefined-23.4 M undefined
20140 undefined-23.47 M undefined-21.88 M undefined
20130 undefined-100,000 undefined-150,000 undefined
20120 undefined-110,000 undefined-110,000 undefined

Viking Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
000000000000000.020.10.381.082.09
--------------1,050.00313.04304.21180.9993.23
-------------------
0000000000000000000
00-0.02-0.02-0.01-0.02-0.02-0.03-0.04-0.05-0.07-0.09-0.11-0.18-0.24-0.27-0.010.461.2
---9.52-39.1342.8610.0013.6456.0038.4625.9325.0028.2462.3935.5913.75-95.97-4,290.91160.30
8.658.658.656.3616.2825.9857.5871.9672.677.276.8394.35109.04000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Viking Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Viking Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2012201320142015201620172018201920202021202220232024
                         
00.20.814.113.220.6301.5275.6248.4202.1155.5362.08902.61
0000000000000
0000000000000
0000000000000
0001.10.81.30.67.97.78.411.65.154.6
00.20.815.21421.9302.1283.5256.1210.5167.1367.23907.22
00000000.60.301.41.131
0000000000000
0000000000000
0000000000000
0000000000000
002.30.20.60.30.20.20.10.10.10.140.1
002.30.20.60.30.20.80.40.11.51.271.11
00.23.115.414.622.2302.3284.3256.5210.6168.6368.49908.32
                         
0000000000000
0000.050.070.090.40.410.410.430.450.731.37
-0.1-0.3-22.1-45.5-60.3-80.9-102.9-128.7-168.2-223.2-292-377.94-487.91
000000-0.40-0.1-0.5-1.1-0.39-0.79
0000000000000
-0.1-0.3-22.18.8813.4297.8277.1244.3201.9152.2355.21880.28
0.10.11.80.61.21.512.441.48.57.519.81
0020.31.41.32.33.64.38.17.313.411.6217.6
000.100.71.40000000
0000000000000
000.303.33.50000000
0.10.122.526.58.74.66.712.18.721.919.1327.41
00.21.32.2000000000
0000000000000
00.11.42.60000.4001.30.940.63
00.32.74.80000.4001.30.940.63
0.10.425.26.86.58.74.67.112.18.723.220.0728.04
00.13.115.614.522.1302.4284.2256.4210.6175.4375.28908.32
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Viking Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Viking Therapeutics's financial health and stability.

Assets

Viking Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Viking Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Viking Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Viking Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
00-21-23-14-20-22-25-39-54-68-85
000000000000
000000000000
00210010-37-2103
00-116455815161825
000000000000
000000000000
00-1-8-11-14-18-24-21-47-48-73
000000000000
000-133-1-2657413754-179
000-133-1-2657413754-179
000000000000
002000-300000
000251123305117-56
0022210223000064271
000-3-10000010264
000000000000
00002515-1620-21018
-0.05-0.08-1.59-8.73-11.07-14.76-18.76-24.75-21.78-47.59-48.4-73.38
000000000000

Viking Therapeutics stock margins

The Viking Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Viking Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Viking Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Viking Therapeutics's sales revenue. A higher gross margin percentage indicates that the Viking Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Viking Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Viking Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Viking Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Viking Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Viking Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Viking Therapeutics Margin History

Viking Therapeutics Gross marginViking Therapeutics Profit marginViking Therapeutics EBIT marginViking Therapeutics Profit margin
2030e0 %0 %57.57 %
2029e0 %27.09 %42.79 %
2028e0 %-27.19 %-2.91 %
2027e0 %-352.63 %-286.06 %
2026e0 %-1,193.96 %-1,039.4 %
2025e0 %-10,025.49 %-8,355.7 %
20240 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

Viking Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Viking Therapeutics earnings per share therefore indicates how much revenue Viking Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Viking Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Viking Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Viking Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Viking Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Viking Therapeutics Revenue, EBIT and net profit per share

DateViking Therapeutics Sales per ShareViking Therapeutics EBIT per shareViking Therapeutics Earnings per Share
2030e18.69 undefined0 undefined10.76 undefined
2029e9.67 undefined0 undefined4.14 undefined
2028e3.45 undefined0 undefined-0.1 undefined
2027e0.86 undefined0 undefined-2.45 undefined
2026e0.21 undefined0 undefined-2.15 undefined
2025e0.02 undefined0 undefined-1.59 undefined
20240 undefined-1.38 undefined-1.01 undefined
20230 undefined-1.07 undefined-0.91 undefined
20220 undefined-0.92 undefined-0.9 undefined
20210 undefined-0.72 undefined-0.71 undefined
20200 undefined-0.59 undefined-0.54 undefined
20190 undefined-0.45 undefined-0.36 undefined
20180 undefined-0.45 undefined-0.38 undefined
20170 undefined-0.73 undefined-0.79 undefined
20160 undefined-0.85 undefined-0.9 undefined
20150 undefined-1.89 undefined-3.68 undefined
20140 undefined-2.71 undefined-2.53 undefined
20130 undefined-0.01 undefined-0.02 undefined
20120 undefined-0.01 undefined-0.01 undefined

Viking Therapeutics business model

Viking Therapeutics Inc. is a biotechnology company specializing in the development of drugs for the treatment of metabolic and endocrine disorders. It was founded in 2012 by Brian Lian, Ph.D., and is headquartered in San Diego, California. The company's business model focuses on targeting liver X receptors (LXRs) for the treatment of metabolic disorders. Viking Therapeutics aims to develop treatment options for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as osteoporosis and hypothyroidism. Their lead products in development are VK2809 for NAFLD/NASH and VK5211 for osteoporosis. The company has a promising product pipeline and aims to improve the lives of millions of patients. Viking Therapeutics is one of the most popular companies on Eulerpool.com.

Viking Therapeutics SWOT Analysis

Strengths

Viking Therapeutics Inc has several strengths that contribute to its competitive advantage:

  • Strong research and development capabilities, allowing the company to innovate and develop effective therapeutic solutions.
  • Promising pipeline of drugs, offering potential for growth and diversification.
  • Experienced management team with a track record of success in the biotechnology industry.
  • Strong financial position, enabling investments in research, development, and marketing efforts.

Weaknesses

Despite its strengths, Viking Therapeutics Inc also faces certain weaknesses:

  • Reliance on a limited number of drug candidates, which increases the risk of failure or setbacks in clinical trials.
  • Limited marketing and distribution capabilities, potentially hampering the company's ability to reach a wider customer base.
  • Highly competitive industry, with established players and larger pharmaceutical companies that may have more resources and market presence.
  • Dependency on regulatory approvals, as delays or rejections can significantly impact product launches and revenue generation.

Opportunities

Viking Therapeutics Inc can capitalize on the following opportunities:

  • Growing demand for innovative therapies and treatments in the healthcare industry.
  • Expanding partnerships and collaborations with other biotech or pharmaceutical companies to accelerate research and development efforts.
  • Entry into new markets or therapeutic areas to diversify the company's revenue streams.
  • Potential for strategic acquisitions or licensing agreements to enhance the company's portfolio and increase market presence.

Threats

Viking Therapeutics Inc faces several threats that could impact its business and growth:

  • Stringent regulatory requirements and potential changes in regulations that may hinder the approval process for new drugs.
  • Intense competition from both existing and emerging biotech and pharmaceutical companies.
  • Economic downturns or market volatility that can affect investor confidence and funding opportunities.
  • Failure of clinical trials or unexpected side effects associated with the company's drug candidates.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Viking Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Viking Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Viking Therapeutics shares outstanding

The number of shares was Viking Therapeutics in 2024 — This indicates how many shares 109.037 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Viking Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Viking Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Viking Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Viking Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Viking Therapeutics.

Viking Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2024-0.28 -0.32  (-13.72 %)2024 Q4
9/30/2024-0.26 -0.22  (14.36 %)2024 Q3
6/30/2024-0.28 -0.2  (27.38 %)2024 Q2
3/31/2024-0.28 -0.26  (8.32 %)2024 Q1
12/31/2023-0.26 -0.25  (3.25 %)2023 Q4
9/30/2023-0.22 -0.23  (-2.91 %)2023 Q3
6/30/2023-0.2 -0.19  (3.16 %)2023 Q2
3/31/2023-0.24 -0.25  (-2.12 %)2023 Q1
12/31/2022-0.24 -0.26  (-9.98 %)2022 Q4
9/30/2022-0.24 -0.21  (10.87 %)2022 Q3
1
2
3
4

Eulerpool ESG Scorecard© for the Viking Therapeutics stock

Eulerpool World ESG Rating (EESG©)

34/ 100

🌱 Environment

35

👫 Social

46

🏛️ Governance

21

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Viking Therapeutics shareholders

%
Name
Stocks
Change
Date
14.75020 % Fidelity Management & Research Company LLC16,456,803234,2476/30/2024
9.03192 % The Vanguard Group, Inc.10,076,9102,309,0686/30/2024
4.24139 % BlackRock Institutional Trust Company, N.A.4,732,114-2,002,5056/30/2024
4.18227 % State Street Global Advisors (US)4,666,157-456,2719/30/2024
3.24108 % Ligand Pharmaceuticals Inc3,616,077-2,449,0033/29/2023
2.06590 % Lian (Brian)2,304,927-50,0009/20/2024
1.84795 % JP Morgan Asset Management2,061,7581,242,7506/30/2024
1.66629 % Geode Capital Management, L.L.C.1,859,082-467,6976/30/2024
1.25904 % Susquehanna International Group, LLP1,404,7151,118,7986/30/2024
1.23812 % Pictet Asset Management Ltd.1,381,3743,3386/30/2024
1
2
3
4
5
...
10

Viking Therapeutics Executives and Management Board

Dr. Brian Lian

(57)
Viking Therapeutics President, Chief Executive Officer, Director (since 2012)
Compensation 5.41 M

Ms. Marianne Mancini

(58)
Viking Therapeutics Chief Operating Officer
Compensation 2.05 M

Mr. Greg Zante

(52)
Viking Therapeutics Chief Financial Officer
Compensation 1.71 M

Dr. Lawson Macartney

(65)
Viking Therapeutics Independent Chairman of the Board
Compensation 161,553

Mr. J. Matthew Singleton

(70)
Viking Therapeutics Independent Director
Compensation 131,603
1
2

Viking Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Ligand Pharmaceuticals Stock
Ligand Pharmaceuticals
SupplierCustomer0,870,880,830,940,660,38
1

Most common questions regarding Viking Therapeutics

What values and corporate philosophy does Viking Therapeutics represent?

Viking Therapeutics Inc represents values of innovation, integrity, and patient-centricity. As a biopharmaceutical company, Viking Therapeutics is committed to developing novel treatments for metabolic and endocrine disorders. The company's corporate philosophy emphasizes a research-driven approach, ensuring the highest quality in drug discovery and development. Viking strives for transparency and ethical practices in all aspects of its operations. With a focus on improving patients' lives through therapeutic advancements, Viking Therapeutics remains dedicated to revolutionizing the treatment options available in the healthcare industry.

In which countries and regions is Viking Therapeutics primarily present?

Viking Therapeutics Inc, a renowned pharmaceutical company, primarily operates in the United States. With a strong focus on the development of novel therapies for metabolic and endocrine disorders, Viking Therapeutics actively engages in clinical research and collaboration within the US market. By leveraging innovative approaches and strategic partnerships, Viking Therapeutics Inc aims to address critical medical needs and improve patients' lives. With its headquarters based in San Diego, California, Viking Therapeutics remains committed to advancing transformative treatments within the domestic pharmaceutical landscape.

What significant milestones has the company Viking Therapeutics achieved?

Viking Therapeutics Inc has achieved several significant milestones. Firstly, the company successfully completed Phase 2 clinical trials for its lead product candidate VK2809, demonstrating its potential to treat fatty liver disease. Additionally, Viking Therapeutics received FDA orphan drug designation for VK2809 in the treatment of glycogen storage disease type Ia. The company also announced positive results from Phase 2 clinical trials for VK5211, a potential treatment for muscle loss. Viking Therapeutics' achievements demonstrate its dedication to advancing innovative therapies in areas of high unmet medical needs, making it a promising player in the pharmaceutical industry.

What is the history and background of the company Viking Therapeutics?

Viking Therapeutics Inc is a biopharmaceutical company specializing in the development of novel therapies for metabolic and endocrine disorders. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California. The company is dedicated to advancing its pipeline of innovative drug candidates, aiming to address the significant unmet medical needs in areas like non-alcoholic steatohepatitis (NASH) and hip fracture recovery. Viking Therapeutics' research focuses on the role of specific receptors in modulating metabolic and hormonal pathways, targeting diseases that affect millions worldwide. With a strong commitment to scientific excellence, Viking Therapeutics strives to deliver groundbreaking treatments to improve patient outcomes and quality of life.

Who are the main competitors of Viking Therapeutics in the market?

The main competitors of Viking Therapeutics Inc in the market include Amgen Inc, Intercept Pharmaceuticals Inc, and Gilead Sciences Inc.

In which industries is Viking Therapeutics primarily active?

Viking Therapeutics Inc is primarily active in the pharmaceutical industry, specifically focusing on the development of novel therapies for metabolic and endocrine disorders. With a strong emphasis on addressing unmet medical needs, Viking Therapeutics aims to provide innovative solutions for patients suffering from conditions like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Through their extensive research and development efforts, Viking Therapeutics is committed to improving the lives of individuals affected by these diseases.

What is the business model of Viking Therapeutics?

The business model of Viking Therapeutics Inc revolves around developing novel therapeutics for metabolic and endocrine disorders. The company focuses on researching and developing small molecule drugs that target specific biological pathways to address conditions such as non-alcoholic steatohepatitis (NASH), hip fracture recovery, and other metabolic diseases. Viking Therapeutics aims to provide innovative solutions to unmet medical needs by advancing its pipeline of drug candidates through rigorous scientific research and clinical trials. By leveraging its expertise in drug discovery and development, Viking Therapeutics strives to improve the lives of patients and deliver value to its stakeholders.

What is the P/E ratio of Viking Therapeutics 2025?

The P/E ratio cannot be calculated for Viking Therapeutics at the moment.

What is the P/S ratio of Viking Therapeutics 2025?

The P/S cannot be calculated for Viking Therapeutics currently.

What is the Quality Investing of Viking Therapeutics?

The Quality Investing for Viking Therapeutics is 4/10.

What is the revenue of Viking Therapeutics 2025?

The expected Viking Therapeutics revenue is 2.13 M USD.

How high is the profit of Viking Therapeutics 2025?

The expected Viking Therapeutics profit is -177.56 M USD.

What is the business model of Viking Therapeutics

Viking Therapeutics Inc. is a biopharmaceutical company focused on the development of drugs for metabolic and endocrine diseases. The company was founded in 2012 and is headquartered in San Diego, California. Viking Therapeutics currently offers two main products: VK2809 and VK5211. VK2809 is a selective thyroid hormone receptor beta agonist developed for the treatment of fatty liver disease and hypercholesterolemia. VK5211 is a selective androgen receptor modulator used for the treatment of muscle wasting and weakness, as well as for supporting rehabilitation measures. Both VK2809 and VK5211 are still in various stages of clinical development and have shown promising results. In clinical studies, VK2809 has shown the ability to achieve significant improvements in liver function and cholesterol levels. VK5211 has also shown positive results in clinical studies by increasing muscle strength and mass in patients with muscle wasting. Viking Therapeutics has also entered into a research collaboration with Ligand Pharmaceuticals, a leading provider of ligand technology. The partnership aims to discover and develop additional potential drug candidates that address a broader range of diseases. The business model of Viking Therapeutics is based on the development and commercialization of new drugs targeting specific disease areas. The company uses an innovative scientific approach to develop potential therapies that build on existing biological processes in the body. These drugs are specifically tailored to the needs of patients with metabolic and endocrine disorders. In addition, Viking Therapeutics relies on careful selection of study centers for conducting clinical trials. The company selects centers that have extensive experience in clinical research and adhere to the strictest standards for conducting clinical trials. Viking Therapeutics primarily finances its research and development projects through equity and debt financing. As part of its business strategy, the company also seeks partnerships and licensing agreements with other companies to expand the distribution of its products and services. In summary, Viking Therapeutics' business model is focused on developing and marketing novel therapies for metabolic and endocrine diseases. Through collaboration with various research institutions and leveraging its scientific expertise, the company is able to develop promising medical solutions for patients with severe metabolic disorders and other conditions.

What is the Viking Therapeutics dividend?

Viking Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Viking Therapeutics pay dividends?

The dividend cannot currently be calculated for Viking Therapeutics or the company does not pay out a dividend.

What is the Viking Therapeutics ISIN?

The ISIN of Viking Therapeutics is US92686J1060.

What is the Viking Therapeutics WKN?

The WKN of Viking Therapeutics is A12GD6.

What is the Viking Therapeutics ticker?

The ticker of Viking Therapeutics is VKTX.

How much dividend does Viking Therapeutics pay?

Over the past 12 months, Viking Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Viking Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Viking Therapeutics?

The current dividend yield of Viking Therapeutics is .

When does Viking Therapeutics pay dividends?

Viking Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Viking Therapeutics?

Viking Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Viking Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Viking Therapeutics located?

Viking Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Viking Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Viking Therapeutics from 2/15/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/15/2025.

When did Viking Therapeutics pay the last dividend?

The last dividend was paid out on 2/15/2025.

What was the dividend of Viking Therapeutics in the year 2024?

In the year 2024, Viking Therapeutics distributed 0 USD as dividends.

In which currency does Viking Therapeutics pay out the dividend?

The dividends of Viking Therapeutics are distributed in USD.

All fundamentals about Viking Therapeutics

Our stock analysis for Viking Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Viking Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.